JP2017524031A - ガンマデルタｔ細胞およびその使用 - Google Patents

ガンマデルタｔ細胞およびその使用 Download PDF

Info

Publication number
JP2017524031A
JP2017524031A JP2017521620A JP2017521620A JP2017524031A JP 2017524031 A JP2017524031 A JP 2017524031A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017524031 A JP2017524031 A JP 2017524031A
Authority
JP
Japan
Prior art keywords
cells
gamma delta
cell
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524031A5 (cg-RX-API-DMAC10.html
Inventor
マイケル リーク
マイケル リーク
アデーレ ハンニガン
アデーレ ハンニガン
Original Assignee
ティーシー バイオファーム リミテッド
ティーシー バイオファーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201412175A external-priority patent/GB201412175D0/en
Priority claimed from GB201415379A external-priority patent/GB201415379D0/en
Priority claimed from GBGB1506423.1A external-priority patent/GB201506423D0/en
Application filed by ティーシー バイオファーム リミテッド, ティーシー バイオファーム リミテッド filed Critical ティーシー バイオファーム リミテッド
Publication of JP2017524031A publication Critical patent/JP2017524031A/ja
Publication of JP2017524031A5 publication Critical patent/JP2017524031A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/43—Protozoan antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017521620A 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用 Pending JP2017524031A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201412175A GB201412175D0 (en) 2014-07-09 2014-07-09 Gamma T cells and uses thereof
GB1412175.0 2014-07-09
GB201415379A GB201415379D0 (en) 2014-08-29 2014-08-29 Gamma T cells and uses thereof
GB1415379.5 2014-08-29
GB1506423.1 2015-04-15
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020115432A Division JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2017524031A true JP2017524031A (ja) 2017-08-24
JP2017524031A5 JP2017524031A5 (cg-RX-API-DMAC10.html) 2018-08-16

Family

ID=53776892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017521620A Pending JP2017524031A (ja) 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Country Status (12)

Country Link
US (2) US20170196910A1 (cg-RX-API-DMAC10.html)
EP (1) EP3167050A1 (cg-RX-API-DMAC10.html)
JP (3) JP2017524031A (cg-RX-API-DMAC10.html)
KR (1) KR20170045205A (cg-RX-API-DMAC10.html)
CN (1) CN107075480A (cg-RX-API-DMAC10.html)
AU (1) AU2015287456A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017000464A2 (cg-RX-API-DMAC10.html)
CA (1) CA2954546A1 (cg-RX-API-DMAC10.html)
EA (1) EA201790010A1 (cg-RX-API-DMAC10.html)
IL (1) IL249970B (cg-RX-API-DMAC10.html)
SG (1) SG11201700134PA (cg-RX-API-DMAC10.html)
WO (1) WO2016005752A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN107106578B (zh) * 2014-08-12 2020-12-25 香港大学 治疗厄泼斯坦-巴尔病毒相关疾病的双膦酸盐化合物和γδT细胞-介导的疗法
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
EP3490675A4 (en) * 2016-07-29 2020-07-29 New York University T GAMMA DELTA LYMPHOCYTES USED AS A TARGET FOR THE TREATMENT OF SOLID TUMORS
TW201814042A (zh) * 2016-09-26 2018-04-16 新加坡商泰莎治療私人有限公司 T細胞擴展方法
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
WO2019147735A1 (en) 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
US12698340B2 (en) 2018-10-01 2026-08-04 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors
BR112021006182A2 (pt) 2018-10-01 2021-06-29 Adicet Bio, Inc. composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
CA3127103A1 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
CA3250985A1 (en) 2022-02-16 2023-08-24 Priothera Sas CAR CELL TREATMENT METHODS IN COMBINATION WITH S1P RECEIVER MODULATORS
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2003529363A (ja) * 2000-04-03 2003-10-07 ヘモソル インコーポレーテッド ＴｃＲガンマデルタＴ細胞の産生
JP2008509683A (ja) * 2004-08-19 2008-04-03 ユニバーシティ オブ ベルン 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
DK1930414T3 (da) 2005-09-08 2012-10-22 Medinet Co Ltd Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2003529363A (ja) * 2000-04-03 2003-10-07 ヘモソル インコーポレーテッド ＴｃＲガンマデルタＴ細胞の産生
JP2008509683A (ja) * 2004-08-19 2008-04-03 ユニバーシティ オブ ベルン 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Also Published As

Publication number Publication date
AU2015287456A1 (en) 2017-02-02
EP3167050A1 (en) 2017-05-17
CN107075480A (zh) 2017-08-18
US20170196910A1 (en) 2017-07-13
SG11201700134PA (en) 2017-02-27
WO2016005752A1 (en) 2016-01-14
IL249970B (en) 2019-11-28
EA201790010A1 (ru) 2017-05-31
JP2020172522A (ja) 2020-10-22
KR20170045205A (ko) 2017-04-26
IL249970A0 (en) 2017-03-30
BR112017000464A2 (pt) 2017-11-07
JP2023123437A (ja) 2023-09-05
CA2954546A1 (en) 2016-01-14
US20210030794A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
JP2023123437A (ja) ガンマデルタｔ細胞およびその使用
JP6995624B2 (ja) 修正ガンマデルタｔ細胞およびその使用
JP7258364B2 (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
Wu et al. Human γδT-cell subsets and their involvement in tumor immunity
Li et al. MART-1–specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro
JP2025092558A (ja) 養子細胞療法のための改良型細胞培養方法
CN103756964B (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
Spel et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
US20160208216A1 (en) Methods of cell culture for adoptive cell therapy
EP3227435B1 (en) Gammadelta t cell expansion procedure
CN113766919B (zh) 制造抗bcma car t细胞
TW201729818A (zh) 製備用於ｔ細胞治療之ｔ細胞的方法
CN104321425A (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
CN107002039A (zh) 使用t细胞用于培养自然杀伤细胞的方法
Khammari et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
US11473059B2 (en) Method for enrichment and expansion of virus antigen-specific T cells
JP2017061558A (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
CA3107515A1 (en) Method for tumor treatment with immune effector cells
Zhou et al. Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients
Li et al. CAR-X cell engineering
WO2025095114A1 (ja) 改善された白血球の製造方法
WO2026096743A1 (en) Methods for gamma delta t cells manufacturing
CN121752714A (zh) 用于培养t细胞的组合物和方法
EA043265B1 (ru) Модифицированные гамма-дельта-t-клетки и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303